Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCDIN3D | Q7Z5W3 | 14/20 | 0.46 |
| ▸ | PDE9A | O76083 | 3/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467391 | 0.92 | PDE9A (0.39) | BCDIN3DPDE9APDE1C | |
| SCHEMBL5491442 | 0.90 | ALDH1A1 (0.46) | BCDIN3DPDE9APDE1C | |
| SCHEMBL5473490 | 0.89 | BCDIN3D (0.38) | BCDIN3DPDE9APDE1CTRPV1 | |
| SCHEMBL14431715 | 0.78 | TRPV1 (0.52) | BCDIN3DPDE9APDE1CTRPV1 | |
| SCHEMBL5491903 | 0.78 | TRPV1 (0.52) | BCDIN3DPDE9APDE1CTRPV1 | |
| SCHEMBL5486026 | 0.75 | MAPT (0.57) | TRPV1 | |
| SCHEMBL4908491 | 0.73 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL5472038 | 0.70 | TRPV1 (0.44) | BCDIN3DPDE9APDE1CTRPV1 | |
| SCHEMBL14431714 | 0.70 | TRPV1 (0.44) | BCDIN3DPDE9APDE1CTRPV1 | |
| SCHEMBL5472035 | 0.67 | MAPT (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197559-A1 | Aryl substituted purine analogues | ADORA2A, GART, P2RX7 | BCDIN3D 1858/4885PDE9A 409/4885PDE1C 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.